Fabry Disease Market Expected to Experience Growth by 2032, Predicts DelveInsight | Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics

Fabry Disease Market Expected to Experience Growth by 2032, Predicts DelveInsight | Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics
Fabry Disease Market

DelveInsight’s “Fabry Disease Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Fabry Disease, historical and forecasted epidemiology as well as the Fabry Disease market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.               

The Fabry Disease market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Fabry Disease market size from 2019 to 2032, segmented by seven major markets. The Report also covers current Fabry Disease treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Fabry Disease market.


Request for a Free Sample Report @  Fabry Disease Market Forecast


Some facts of the Fabry Disease Market Report are:

  • According to DelveInsight, Fabry Disease market size is expected to grow at a decent CAGR by 2032.
  • Fabry Disease Market Size was highest in the US among the 7MM in the 2022, accounting for approximately USD 625 million which is further expected to increase by 2032.
  • As per the estimates, the total Fabry disease prevalent cases in the 7MM were approximately 13K in 2021.
  • Leading Fabry Disease companies working in the market are Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, Shire, Takeda, Amicus Therapeutics, Protalix, uniQure, Codexis, MP6 Therapeutics, CellGenTech, and others.
  • Key Fabry Disease Therapies expected to launch in the market are PRX-102 (Pegunigalsidase Alfa), Venglustat, ST-920, FLT190, 4D-310, Lucerastat, Moss-aGal, and others.
  • Freeline Therapeutics decided to pause the clinical development of FLT190, an experimental gene therapy for Fabry disease. The company shifted its focus to advancing FLT201, a gene therapy for Gaucher disease. As a result, the MARVEL-1 clinical trial testing FLT190’s safety and efficacy in Fabry patients was terminated. FLT190 uses a modified liver-directed adeno-associated virus to deliver a healthy version of the GLA gene, which provides instructions to produce alpha-gal A.
  • Adults with Fabry disease demonstrated strong adherence to at-home Galafold treatment, which must be taken every other day on an empty stomach. The MALTA-FABRY study highlighted consistent quality of life among patients, accompanied by decreasing levels of pain and physical limitations over time.


Fabry Disease Overview

Fabry disease is an inherited lysosomal storage disorder caused by a nonfunctional or partially functional enzyme called alpha-galactosidase A (-Gal A). Reduced -Gal A activity in lysosomes leads to the accumulation of enzyme substrates (Gb3 and lyso-Gb3), which causes cellular damage in tissues throughout the body.

Despite being X-linked, heterozygous women may experience all of the signs and symptoms seen in men; however, when compared to hemizygous males, the signs and symptoms of Fabry disease in women typically appear later and with less severity.

Fabry disease symptoms include pain that spreads throughout the body (called a Fabry crisis), gastrointestinal complications, headaches, impaired sweating, vertigo, and hearing loss. Several tests, such as enzyme assay and newborn screening, are used for Fabry disease diagnosis.


Learn more about Fabry Disease treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ https://www.delveinsight.com/sample-request/fabry-disease-market


Fabry Disease Market 

The Fabry Disease market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Fabry Disease market trends by analyzing the impact of current Fabry Disease therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Fabry Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Fabry Disease market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, the Fabry Disease market in 7MM is expected to witness a major change in the study period 2019-2032.


Fabry Disease Market Drivers:

  • Growing Awareness: Increased awareness about Fabry disease among healthcare professionals, patients, and the general public has led to better diagnosis rates. As understanding of the disease improves, more patients seek medical attention, contributing to market growth.
  • Advancements in Treatment Options: Ongoing research and development efforts have resulted in novel therapies for Fabry disease. These advancements provide hope for better management and improved quality of life for patients.
  • Rising Prevalence: The prevalence of Fabry disease is gradually increasing. As more cases are diagnosed, the demand for effective treatments rises, driving market expansion.


Fabry Disease Epidemiology 

The Fabry Disease epidemiology section provides insights into the historical and current Fabry Disease patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Fabry Disease market report also provides the diagnosed patient pool, trends, and assumptions. 


Explore more about Fabry Disease Epidemiology @ Fabry Disease Market Dynamics


Fabry Disease Drugs Uptake

This section focuses on the uptake rate of the potential Fabry Disease drugs recently launched in the Fabry Disease market or expected to be launched in 2019-2032. The analysis covers the Fabry Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.   

Fabry Disease Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Fabry Disease market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.


Fabry Disease Pipeline Development Activities

The Fabry Disease report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Fabry Disease key players involved in developing targeted therapeutics.


Request for a sample report to understand more about the Fabry Disease pipeline development activities @ https://www.delveinsight.com/sample-request/fabry-disease-market


Fabry Disease Pipeline Therapies and Key Companies

  • PRX-102 (Pegunigalsidase Alfa): Protalix Biotherapeutics
  • Venglustat: Sanofi Genzyme
  • ST-920: Sangamo Therapeutics
  • FLT190: Freeline Therapeutics
  • 4D-310: 4D Molecular Therapeutics
  • Lucerastat: Idorsia Pharmaceuticals


Fabry Disease Therapeutics Assessment

Major key companies are working proactively in the Fabry Disease Therapeutics market to develop novel therapies which will drive the Fabry Disease treatment markets in the upcoming years are Protalix Biotherapeutics, Sanofi Genzyme, Sangamo Therapeutics, Freeline Therapeutics, 4D Molecular Therapeutics, Idorsia Pharmaceuticals, GREENOVATION BIOTECH GMBH, Shire, Takeda, Amicus Therapeutics, Protalix, uniQure, Codexis, MP6 Therapeutics, CellGenTech, and others.


Learn more about the emerging Fabry Disease therapies & key companies @ https://www.delveinsight.com/sample-request/fabry-disease-market


Fabry Disease Report Key Insights

1. Fabry Disease Patient Population

2. Fabry Disease Market Size and Trends

3. Key Cross Competition in the Fabry Disease Market

4. Fabry Disease Market Dynamics (Key Drivers and Barriers)

5. Fabry Disease Market Opportunities

6. Fabry Disease Therapeutic Approaches

7. Fabry Disease Pipeline Analysis

8. Fabry Disease Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Fabry Disease Market


Table of Contents

1. Key Insights

2. Executive Summary

3. Fabry Disease Competitive Intelligence Analysis

4. Fabry Disease Market Overview at a Glance

5. Fabry Disease Disease Background and Overview

6. Fabry Disease Patient Journey

7. Fabry Disease Epidemiology and Patient Population

8. Fabry Disease Treatment Algorithm, Current Treatment, and Medical Practices

9. Fabry Disease Unmet Needs

10. Key Endpoints of Fabry Disease Treatment

11. Fabry Disease Marketed Products

12. Fabry Disease Emerging Therapies

13. Fabry Disease Seven Major Market Analysis

14. Attribute Analysis

15. Fabry Disease Market Outlook (7 major markets)

16. Fabry Disease Access and Reimbursement Overview

17. KOL Views on the Fabry Disease Market

18. Fabry Disease Market Drivers

19. Fabry Disease Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer


About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +91-9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting/conference-coverage-services